Emergent BioSolutions acquires Cangene Corporation

Emergent BioSolutions Inc. completed its acquisition of Cangene Corporation by way of plan of arrangement for US$222 million in cash. Consistent with Emergent's growth plan, the acquisition expands its biodefense product portfolio with the addition of marketed therapeutics distributed to hospitals and specialty clinics using an established commercial infrastructure.

Headquartered in Rockville, Maryland, Emergent BioSolutions is a global pharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats.

Cangene, headquartered in Winnipeg, Manitoba, is a biopharmaceutical company that develops and commercializes specialty therapeutics.

Emergent's in-house team was led by A.B. Cruz, Executive Vice President and General Counsel, and included Emma Wheatley, Vice President and Deputy General Counsel; Eric Burt, Assistant General Counsel; and Thomas Gillespie, Senior Counsel, Corporate and IP.  Emergent was represented in Canada by McCarthy Tétrault LLP with a team led by Graham Gow and Ian Michael and including Shanon Grauer, Michael Eldridge and Daniel Saposnik (business law); Gabrielle Richards and Elaine Buzzell (tax); Mark Firman (pensions and benefits) and Geoff Hall (litigation); and in the US by DLA Piper LLP with a team led by Howard Schwartz and included Matthew Batters and Nancy Urizar (corporate).

Cangene's legal team was led by Francis St. Hilaire, General Counsel, and assisted in Canada by Miller Thomson LLP with a team led by Robert Forbes and which including Jay Hoffman, Ormonde Benson, Steven Oh and Mara Banack (corporate); Lyne Gaulin (tax), Rosanne Rocchi (pensions and benefits), Lisa Goodfellow (employment), and John Chapman and Nafisah Chowdhury (litigation); and in the US by BakerHostetler LLP with a team led by Steven Goldberg and including Kelley Doran (regulatory), Jonathan Lewis (HSR) and Sean Harrigan Jr. (corporate).